Dr. Lal PathLabs gets nod to acquire 70% stake in SN Genelab

Dr. Lal PathLabs has received approval for the acquisition of 70% stake in SN Genelab (SN Gene) from its existing Shareholders. Post acquisition, SN Gene shall become a Subsidiary of the Company. The Board of Directors in their meeting held on September 24, 2026, inter-alia considered and approved the same. The object of acquisition is to strengthen the company’s expertise in genomics and broaden its portfolio of advanced diagnostic services. The transaction will be completed by November 30, 2026. Impact : The acquisition of a 70% stake in SN Genelab is expected to yield a net-positive long-term structural impact for Dr. Lal PathLabs, despite causing minor short-term margin compression and initial EPS dilution. The integration expands Dr. Lal's high-end genomics and molecular oncology portfolio while strengthening its geographic footprint in Western India and the UAE. View : It has traditionally been dominant in North India, SN Genelab provides it with ready-made premium infrastructure in Gujarat (Surat and Ahmedabad) alongside international testing hubs in Dubai and Ras Al Khaimah. Unlike many diagnostic startups that operate at a loss or at break-even (such as Core Diagnostics, which Metropolis acquired in late 2024 at 2.2x sales while at EBITDA break-even), SN Genelab is highly profitable. It maintains a robust EBITDA margin of 30%, meaning it will immediately contribute profitable cash flow to Dr. Lal PathLabs once consolidated. Disclosure : I do not hold any position in the mentioned stock. Disclaimer : Investment in securities are subject to market risk. This is only for educational purpose.